MED vs. USNA, NUS, NATR, VERU, EL, PBH, IPAR, HLF, FARM, and JVA
Should you be buying Medifast stock or one of its competitors? The main competitors of Medifast include USANA Health Sciences (USNA), Nu Skin Enterprises (NUS), Nature's Sunshine Products (NATR), Veru (VERU), Estée Lauder Companies (EL), Prestige Consumer Healthcare (PBH), Inter Parfums (IPAR), Herbalife (HLF), Farmer Bros. (FARM), and Coffee (JVA).
Medifast vs.
Medifast (NYSE:MED) and USANA Health Sciences (NYSE:USNA) are both small-cap consumer staples companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.
Medifast has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.
USANA Health Sciences received 16 more outperform votes than Medifast when rated by MarketBeat users. However, 63.52% of users gave Medifast an outperform vote while only 60.36% of users gave USANA Health Sciences an outperform vote.
In the previous week, USANA Health Sciences had 24 more articles in the media than Medifast. MarketBeat recorded 25 mentions for USANA Health Sciences and 1 mentions for Medifast. Medifast's average media sentiment score of 0.51 beat USANA Health Sciences' score of 0.23 indicating that Medifast is being referred to more favorably in the media.
USANA Health Sciences has a net margin of 6.30% compared to Medifast's net margin of 0.35%.
95.5% of Medifast shares are held by institutional investors. Comparatively, 54.3% of USANA Health Sciences shares are held by institutional investors. 2.5% of Medifast shares are held by insiders. Comparatively, 0.6% of USANA Health Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Medifast currently has a consensus target price of $16.50, indicating a potential upside of 35.58%. USANA Health Sciences has a consensus target price of $36.00, indicating a potential upside of 33.14%. Given Medifast's higher possible upside, analysts clearly believe Medifast is more favorable than USANA Health Sciences.
Medifast has higher earnings, but lower revenue than USANA Health Sciences. USANA Health Sciences is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.
Summary
Medifast beats USANA Health Sciences on 8 of the 15 factors compared between the two stocks.
Get Medifast News Delivered to You Automatically
Sign up to receive the latest news and ratings for MED and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medifast Competitors List
Related Companies and Tools
This page (NYSE:MED) was last updated on 4/25/2025 by MarketBeat.com Staff
